Brookline starts POINT Biopharma at buy; PT $23

Point Biopharma

Brookline Capital Markets initiated coverage of POINT Biopharma (NASDAQ:PNT) with a “buy” rating and $23 price target. The stock closed at $8.07 on Nov. 30.

POINT is a late-stage clinical oncology company focused on developing and commercializing radiopharmaceuticals. 

The company has two assets in Phase 3 clinical trials for the treatment of prostate and neuroendocrine cancers and an early-stage portfolio of product candidates. “Clinical data reported so far for the company’s two late-stage assets are encouraging with pivotal readouts expected in mid-2022 and 2023,” writes analyst Kemp Dolliver. 

POINT’s PNT2003 combines a somatostatin-specific radioligand with lutetium-177 for the treatment of neuroendocrine tumors. Interim data from an ongoing Phase 3 clinical trial in Canada has been positive, Mr. Dolliver said. The progression-free survival rate at 12 months of 89.3% exceeded pre-specified success thresholds of greater than 60%, he added. 

Management intends to pursue an indication for non-gastroenteropancreatic neuroendocrine tumors initially, followed by an indication for gastroenteropancreatic neuroendocrine tumors. 

POINT’s PNT2002 combines a prostate specific membrane antigen (PSMA)-specific ligand, PSMA-I&T, with the beta-emitting radioisotope lutetium-177 for the treatment of metastatic castration resistant prostate cancer. 

In a prospective clinical trial, Mr. Dolliver said PSMA I&T demonstrated a median radiographic progression-free survival of 13.7 months and median overall survival that was not reached at 28 months, along with no clinically significant adverse events.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.